First clinical evidence spurs Sanofi’s takeout of Vicebio for $1.15B up front

Early data emerging from a clinical study of the first product derived from Vicebio’s vaccine platform have spurred Sanofi’s decision to acquire the start-up for $1.15 billion up front.

The deal gives Sanofi (Euronext:SAN; NASDAQ:SNY) control of London-based Vicebio Ltd.’s Molecular Clamp technology, which confers stability, manufacturing and efficacy benefits on vaccine candidates. The first of those, bivalent product VXB-241 for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), began a Phase I study in September 2024...